Table 3.
Patient | Total lung V20 difference (%) | Tumor site | Disease stage | Prescription dose and fractionation scheme | Hypofx? | |
---|---|---|---|---|---|---|
10 | 2.59 | Squamous mid‐esophagus | T3N1M0 | 50.4 Gy, 28 fractions | No | |
5 | 1.82 | NSCLC LUL | T1N2M0 | 63 Gy, 35 fractions | No | |
9 | 1.47 | NSCLC RUL | T1N2M1 | 60 Gy, 30 fractions | No | |
3 | 1.19 | Adenocarcinoma, distal esophagus | T3N1M0 | 50.4 Gy, 28 fractions | No | |
8 | 1.14 | Adenocarcinoma RUL | T1N1M0 recurrent | 63 Gy, 30 fractions | No | |
2 | 0.69 | NSCLC RLL (post surgery) | T2M2N0 | 50.4 Gy, 28 fractions | No | |
7 | 0.52 | Squamous‐cell carcinoma RLL | T2N2M0 | 63 Gy, 35 fractions | No | |
6 |
|
NSCLC LUL | T1N0M0 | 50 Gy, 4 fractions | Yes | |
1 | 0.08 | NSCLC left lung | T3N2M1 | 60 Gy, 20 fractions | No | |
4 |
|
NSCLC RUL | T1N0M0 | 70 Gy, 35 fractions | No |
; ; ; ; ; .